Literature DB >> 9531525

Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.

Y Zhang1, X Guo, E T Lin, L Z Benet.   

Abstract

K02 (morpholine-urea-Phe-Hphe-vinylsulfone), a newly developed peptidomimetic, acts as a potent cysteine protease inhibitor, especially of cathepsins B and L (which are associated with cancer progression) and cruzain (a cysteine protease of Trypanosoma cruzi, which is responsible for Chagas' disease). Here we investigated features of the disposition of K02 using in vitro systems, characterizing the interaction of the drug with human cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), a mediator of multidrug resistance (MDR) to cancer chemotherapy and a countertransporter in the intestine that limits oral drug bioavailability. P-gp functions as an ATP-dependent drug efflux pump to reduce intracellular cytotoxic concentrations. An HPLC assay was developed to analyze K02 and its metabolites formed in human liver microsomes. Three major primary metabolites were determined by LC/MS/MS to be hydroxylated products of the parent compound. A rabbit anti-CYP3A polyclonal antibody (200 microl antibody/mg microsomal protein) produced 75-94% inhibition of the formation of these three hydroxylated metabolites. Ketoconazole (5 microM), a selective CYP3A inhibitor, produced up to 75% inhibition, whereas other CYP-specific inhibitors, i.e. quinidine (CYP2D6), 7,8-benzoflavone (CYP1A2), and sulfaphenazole (CYP2C9), showed no significant effects. An identical metabolite formation profile for K02 was observed with cDNA-expressed human CYP3A4 (Gentest). These data demonstrate that K02 is a substrate for CYP3A. Formation of 1'-hydroxymidazolam, the primary human midazolam metabolite, was markedly inhibited by K02 via competitive processes, which suggests the potential for drug-drug interactions of K02 with other CYP3A substrates. K02 significantly inhibited the photoaffinity labeling of P-gp with azidopine and LU-49888, a photoaffinity analogue of verapamil. Transport studies with [14C]K02, using MDR1-transfected Madin-Darby canine kidney cell monolayers in the Transwell system, demonstrated that the basolateral-to-apical flux of K02 across MDR1-transfected Madin-Darby canine kidney cells was markedly greater than the apical-to-basolateral flux (ratio of 63 with 10 microM [14C]K02). This suggests that K02 is also a P-gp substrate. These studies are important for formulating strategies to increase the absorption and/or decrease the elimination of K02 and to optimize its delivery to malignant cells and parasite-infected host cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531525

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Authors:  K Ito; H Kusuhara; Y Sugiyama
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 3.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

4.  Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.

Authors:  Y H Lee; B A Perry; H S Lee; J R Kunta; J P Sutyak; P J Sinko
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

5.  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

Authors:  M Katoh; M Nakajima; H Yamazaki; T Yokoi
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Authors:  J W Polli; J L Jarrett; S D Studenberg; J E Humphreys; S W Dennis; K R Brouwer; J L Woolley
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

7.  Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.

Authors:  Cheng Li; Cheul-Seol Kim; Jeong-Yeol Yang; Yeong-Jin Park; Jun-Shik Choi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

8.  Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.

Authors:  Y Zhang; L Z Benet
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

9.  Vinyl sulfones as antiparasitic agents and a structural basis for drug design.

Authors:  Iain D Kerr; Ji H Lee; Christopher J Farady; Rachael Marion; Mathias Rickert; Mohammed Sajid; Kailash C Pandey; Conor R Caffrey; Jennifer Legac; Elizabeth Hansell; James H McKerrow; Charles S Craik; Philip J Rosenthal; Linda S Brinen
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

10.  Metabolite Profiling in Anticancer Drug Development: A Systematic Review.

Authors:  Nadda Muhamad; Kesara Na-Bangchang
Journal:  Drug Des Devel Ther       Date:  2020-04-09       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.